BioAlliance suspends liver cancer trial

Following advice from the Drug Safety Monitoring Board, BioAlliance has suspended a Phase II/III trial of doxorubicin Transdrug for liver cancer. The drug did show clinical activity; however, it also resulted in "frequent and more severe pulmonary adverse events than expected," according to BioAlliance. Release